INTRODUCTION
Genomic abnormalities represent one major signature of neoplastic transformation and tumor progression (1). Patterns of chromosome copy number (CN) abnormalities in lung cancer have recently been identified using comparative genomic hybridization (CGH) analysis (2) (3) (4) .
Using array CGH, we recently identified genetic amplification on chromosome 3q26-3qter as the most common genomic abnormality in squamous carcinoma of the lung (5) . The gene coding for the phosphatidylinositol 3-kinase catalytic subunit α (PIK3CA) is responsible for PI3-kinase activity and maps to the peak of this genomic region of amplification (3q26.3) found in squamous carcinoma.
PIK3CA is activated by a series of cell surface tyrosine kinase receptors such as insulin growth factor receptor and platelet-derived growth factor receptor (6). Upon growth factor receptor activation, PIK3CA binds to its heterodimer, p85, and promotes the phosphorylation of Akt at Serine 473 and/or Threonine 308. Akt then activates a series of cancer-related functions such as cell proliferation, cell migration, invasion, and decrease of cell death in human tumors (for review see (7)).
Although the PIK3CA gene has been identified as an oncogene in ovarian (8), cervical (9), and head and neck cancer (10), its exact role in lung cancer development remains unclear.
We have recently shown that PIK3CA gene copy number correlates with increased Akt activity in squamous carcinoma of the lung (5) , implicating the PI3-kinase pathway in lung tumorigenesis. Akt is also known to be activated in airway epithelial cells in vitro after exposure to growth factors such as epidermal growth factor as well as tobacco-related chemicals such as nicotine and NNK (11). In addition, phosphorylated Akt (pAkt) has recently been shown to be overexpressed in 67% of NSCLCs (12) and in preinvasive lesions (13) . Finally, recent attempts to interfere with the PI3-kinase/Akt pathway have shown some promise in lung cancer prevention (14) . All of these lines of evidence strongly indicate a critical role for the PI3-kinase/Akt pathway in lung cancer progression.
Because the PI3-kinase/Akt pathway may have a critical role in lung cancer development, and given that molecular studies of invasive and preinvasive carcinomas of the lung may provide information about progression, staging or recurrence of disease, we asked the following three questions: 1. What is the prevalence of increased PIK3CA gene CN in lung cancer? 2. What is the association between PIK3CA gene CN and phosphorylation of Akt in lung cancer? and 3. At what point does PIK3CA gene amplification or pAkt overexpression take place during lung cancer development? Some of the results of these studies have been previously reported in abstract form (15, 16) .
METHODS (499 words)
Tissue samples and tissue microarrays. Tissue microarrays of NSCLCs were prepared from paraffin blocks following the methods described by (17) and reported earlier (18) . There are 242 tumors represented on the arrays. Hematoxylin and eosin (H&E) stained sections from all tissue blocks were reviewed by our pathologists (A.L.G., J.J.A.).
Fluorescence in situ hybridization (FISH).
BAC clones for specific genes were selected from different libraries: PIK3CA (CTC-364E3), reference clone on 3p (2175D15), and CEP 3 centromeric chromosome 3 (CEP3) probe from Vysis Inc, Downers Grove, IL. Dual color FISH was performed on interphase nuclei in tissue sections as described earlier (5) . The ratio of the mean counts for the test and the reference probes on the opposite chromosome arm of the same chromosome was reported as the relative copy number for the test gene. In preinvasive lesions, we utilized possible deletion of the FHIT locus on Chr. 3p to generate a copy number ratio as a sensitive measure of chromosomal imbalance between 3p and 3q. We previously reported the reliability of the assay by showing low inter-observer variability in FISH spot counting. (18) .
Immunohistochemistry
Immunohistochemical staining was performed as previously described (18) .
Slides were incubated with pAkt primary antibody (Cell Signaling, Beverly, MA) diluted 1:500 in PBS overnight at 4ºC. All immunostains were independently scored by two experienced pathologists (A.L.G., J.J.A). In invasive carcinomas, a pAkt scoring index was created as a combination of the staining intensity and the percentage of positive cells (see Appendix). In preinvasive lesions, however, due to the overall uniformity of staining intensity in the epithelium staining was scored as follows: 0 for no staining, 1+ for weak staining, 2+ moderate staining, and 3+ for strong staining.
Statistical analysis.
Copy number ratios (continuous variable) and scores from immunostains (parametric variables) were tested for correlations and for survival analysis. The average scores of triplicate biopsies were used for FISH analysis. Maximal immunostaining scores from triplicates were used for IHC. Data obtained from the Tumor Registry allowed for survival analysis. Clinical data elements were obtained from the Bioinformatics Core of the Vanderbilt Ingram Cancer Center. Data analysis included Spearman correlation coefficients, ANOVA and Kaplan-Meier survival estimates with Cox proportional hazards regression models. Survival analysis was calculated from date of diagnosis to date of death or last date of contact for those alive at the time of the analysis. Curves were compared by the log-rank test. All analyses were carried out with SAS statistical software (SAS Institute Inc., Cary, NC).
RESULTS
We studied 242 lung cancers on a total of four tissue microarrays. Each lung tumor was assayed in triplicate. The clinical data is summarized in Table 1 . We also studied 43 preinvasive lesions of the lung, 20 low-grade and 23 high-grade.
Amplification of PIK3CA gene copy number in lung cancer
We analyzed PIK3CA gene copy number (CN) in lung cancer by performing dual FISH analysis on four tissue microarrays. We obtained FISH data on 55% of the cases based on the success of the hybridization and the imperfect representation of all tumors in the tissue microarrays. Unsuccessful FISH hybridizations were likely related to extensive formalinfixation of archival materials. Overall, PIK3CA was amplified (CN ratio PIK3CA/Cent3 > 1. 5) in 43% (57/132) of lung tumors analyzed by dual color FISH (Table 2) . When looking at PIK3CA CN ratios by histological groups, we found amplification in 70% (32/46) of squamous cell carcinomas, 19% (9/47) of adenocarcinomas, 38% (6/16) of large cell carcinomas, and 67% (8/12) of small cell lung cancers, 0/4 carcinoid, 0/2 adenosquamous, 0/1 adenocystic, 0/1 sarcoma, and 2/3 NSCLCs showed amplification. A higher degree of amplification (CN ratio > 2) was found in 33% of the tumors, but was most predominant in squamous carcinomas (Table   2 ) where high level amplification accounted for 61% (28/46) of all amplifications. The copy number status for PIK3CA was not associated with age (p=0.1043), smoking duration (p=0.1146), pack years (p=0.4278), nodal status (p=0.3437), stage (p=0.3066), or survival (p=0.6281).
Expression of pAkt in lung cancer and association with PIK3CA amplification
Because of the critical role of an activated Akt pathway in cancer and the possible association with upstream amplification of PIK3CA, we analyzed the level of expression of pAkt in NSCLC by immunohistochemistry. Representative nuclear and cytoplasmic stains for pAkt in normal appearing epithelium and lung tumors are presented in Figure 1 . In normal airway epithelium, pAkt staining was nuclear while the alveolar epithelial cells did not stain.
We found that 83.3% (179/215) of NSCLCs exhibited positive nuclear staining for pAkt (index > 2), while 16.7% (36/215) had strong pAkt nuclear staining (index > 5) without histological preference (Table 3 (6/12), respectively. Small cell lung cancers with strong nuclear staining for pAkt (index > 5) were limited to 8.3% of samples (1/12). A summary of the distribution of both nuclear and cytoplasmic pAkt staining in NSCLCs and SCLCs is presented in Table 3 . PIK3CA gene copy number did not correlate with pAkt nuclear (p=0.4904) or cytoplasmic (p=0.6031) staining in lung cancer.
PIK3CA copy number and pAkt expression during tumorigenesis
To determine when PIK3CA amplification is observed during the course of tumor progression, we performed dual color FISH for PIK3CA in 43 preinvasive bronchial lesions obtained at the time of bronchoscopy from 39 patients. Clinical information was available on 14 patients showed that preinvasive lesions were synchronous to invasive tumors in all 14. We found an increased CN ratio for PIK3CA/FHIT in high-grade lesions [moderate dysplasia, severe dysplasia, carcinoma in situ (CIS)] that was significantly different from the CN ratio in low-grade lesions or in normal epithelium (ANOVA, p<0.001) (Figure 2 ). Severe dysplasia and CIS were almost invariably amplified for PIK3CA ( Figure 3 ).
We found weak immunostaining for pAkt in 8/10 normal bronchial specimens; the remaining two were negative. While the bronchial smooth muscle, stroma, and alveolar tissue were negative, the submucosal glandular epithelium showed 2 + staining. In low-grade preinvasive lesions, immunostaining was weak with only 2/12 (16.7%) showing focal moderate to strong immunopositivity. In contrast, in high-grade preinvasive lesions 11/16 (69%) showed moderate to strong immunopositivity throughout the thickness of the epithelium. Representative immunostains of preinvasive lesions are shown in Figure 4 . There was a significant correlation between copy number increase among the 3 groups (normal, low grade and high grade lesions) and their respective immunostaining scores (spearman correlation coefficient r=0.4, p=0.02).
DISCUSSION
In this study we demonstrate the frequent and early genomic amplification of PIK3CA in lung cancer. Downstream Akt was phosphorylated in a large majority of invasive and preinvasive lung cancers. The level of PIK3CA amplification did not correlate with pAkt immunostaining and is not associated with prognosis. PIK3CA genomic amplification and overexpression was found at the stage of severe dysplasia and likely represents a signature of commitment to tumor progression. These results further implicate the PI3-kinase/pAkt pathway in lung cancer development.
Chromosome 3q26-ter amplification, including the PIK3CA gene locus at the peak of the amplicon, is one of the most prevalent genomic abnormalities in solid tumors and is likely to play a critical role in tumorigenesis. Amplification of chromosome 3q has been described in squamous epithelial transformation from the aerodigestive tract (19) , bladder (20) , cervix (21) and stomach (22) . The 3q amplicon also contains a number of other important genes including p63, hTR, SKL, NEP, and somatostatin. The functions of some of these genes in NSCLC are being investigated. PIK3CA/Cent 3 ratio was increased in 43% (57/132) of lung cancers, which indicates a high frequency of amplification, particularly when compared to other common biomarkers: EGFR is amplified in 22% of NSCLCs (23); ras is mutated 20-30% of lung cancers (24, 25) ; CCND1 (cyclin D1) is amplified 8-30% of lung cancers (26, 27) . Currently, these three genetic alterations and molecular pathways are being targeted for the treatment of lung cancer. In addition, the high prevalence of PIK3CA genomic amplification in preinvasive lesions (85%) and in squamous carcinoma (70%) makes this biomarker very attractive for the development of novel early detection strategies. In addition, phosphorylation of Akt was not found to be a prognostic marker for lung cancer.
When we applied pAkt immunostaining to a large set of tumors, the results failed to show influence on survival in any histological subtype. This suggests that pAkt may have a role in tumor development but not necessarily in progression to a metastatic phenotype.
Understanding the mechanisms of Akt activation is important in fully exploring its usefulness as a therapeutic target. Currently, multiple pathways have been implicated as having roles in Akt activation. First, genomic amplification of PIK3CA or other genes in the pathway may induce changes in the regulation of Akt (5) . Second, k-ras activation (32), growth factor activation, and oncogene activation (EGF, PDGF and IGF), have been shown to be effective mediators of Akt function (33). Third, PTEN is a phosphatase and a tumor suppressor gene that converts phosphatidylinositol-3-phosphate into PI-2 phosphate. Loss of PTEN is associated with an increase in Akt activity, however, its loss is only found in less than 10% of lung cancers (34). Finally, a recent report suggests that PIK3CA might be activated through a point mutation quite uncommon in lung cancer (35). While these data would indicate that multiple pathways might be responsible for early and frequent Akt activation in lung cancer, inhibition of the PI3-kinase/Akt molecular pathway may have the most important therapeutic implications. For example, the identification of patients with increased pAkt expression may be useful in chemopreventive strategies. However, due to the wide range of intracellular functions possessed by PI3-kinase, a broad-spectrum antagonist to its kinase activity may have severe toxicity. Thus, more specific anti-proliferative and pro-apoptotic PI3-kinase inhibitors are being actively pursued, particularly specific inhibitors of Akt (7).
We attempted to validate pAkt immunostaining results by quantifying pAkt expression by Western analysis in a subset of 12 lung tumors. We were unable to demonstrate increased expression of pAkt as compared to total Akt. For unclear reasons, no one has been able to demonstrate pAkt activation in lung primary tumors, which is in contrast to results obtained in lung cell lysates (10). The nature of the antibody and the heterogeneity of lung tumors are likely explanations.
Localization of pAkt in the nucleus and in the cytoplasm confirms previous reports (12), (36). In this study we attempted to obtain clinical information based on the localization of the staining without success. We know that PI3-kinase activity is required for translocation of Akt to the plasma membrane where phosphorylation occurs (37). Akt then phosphorylates a series of important proteins such as p21 and MDM2 in the cytoplasm to allow their nuclear localization (38, 39). Nonetheless, the precise role of Akt in the nucleus remains unclear.
Because PIK3CA amplification appears to be prevalent in preinvasive lung cancer, this cytogenetic abnormality may be a valuable biomarker for identifying cancer early in patients with or at risk for lung cancer. Taking advantage of the frequent 3p deletion on 3p14 in NSCLC (40, 41), we assessed PIK3CA/FHIT copy number ratio, increasing the sensitivity of our assay to detect small genomic abnormalities in tissue sections. Among preinvasive lesions, we found amplification of PIK3CA in high-grade lesions only. Low-grade preinvasive lesions found in the vicinity of invasive tumors did not show PIK3CA amplification. Given the quantifiable nature of PIK3CA copy number by FISH and of pAkt by immunostaining, and to address obvious limitations of a retrospective study, a prospective evaluation of PIK3CA/pAkt as a predictive biomarker for lung cancer development in biopsy specimens from patients at risk for or with lung cancer is warranted. Taking into consideration the fact that not all high-grade lesions develop into invasive tumors (42) , it will be critical to identify a population of high-risk individuals who do and do not develop lung cancer in order to validate these biomarkers as predictors of lung cancer development. The impact of this detection strategy relies on the ultimate ability to shift lung cancer diagnosis towards an earlier stage. This shift by itself could have a major impact on lung cancer management. Presently, there are a number of strategies being investigated for the purpose of achieving a transition towards early detection (sputum cytology, computed tomography), however, the use of biological techniques such as aCGH, FISH, and/or IHC may be the most auspicious (43) . Furthermore, PIK3CA and possibly pAkt may assist in monitoring the response to new chemopreventive agents. Sections were counterstained with hematoxylin and photographed at 40X magnification. Tables   Table 1 Tissue microarrays of NSCLC were prepared from paraffin blocks following the methods described by (E1) and reported earlier (E2) . There are 242 tumors represented on the arrays used in this study: 89 squamous carcinomas, 90 adenocarcinomas (including 16 bronchioalveolar carcinomas), 28 large cell carcinomas, 12 small cell lung cancers, 11 carcinoid tumors, 5 non-small cell carcinomas not otherwise specified, 2 adenosquamous carcinomas, 2 sarcomas, and 1 each of the following: carcinoma in situ, carcinosarcoma, and biphasic pulmonary blastoma. Hematoxylin and eosin (H&E) stained sections from all tissue blocks were reviewed by our pathologists (A.L.G., J.J.A.). Cores 0.6 mm in diameter were taken from the selected area of each specimen and inserted into a recipient paraffin block. Five-micron sections were cut from the arrays and mounted onto charged slides.
Fluorescence in situ hybridization.
BAC clones for specific genes were selected from different libraries: PIK3CA (CTC-364E3), reference clone on 3p (2175D15), and CEP 3 centromeric chromosome 3 (CEP3) probe from Vysis Inc, Downers Grove, IL. Dual color FISH was performed on interphase nuclei in tissue sections as described earlier (E3). Briefly, 2 µg of BAC DNA was labeled by nick-translation with either digoxigenin-dUTP or Cy3-dUTP. Tissue sections were deparaffinized and treated with sodium thiocyanate for 10 min followed by pepsin (4 mg/mL) digestion in 0.2 N HCl for 10 min. Slides were then denatured and incubated with a hybridization mixture consisting of 50% formamide, 2XSSC, Cot-1 DNA, and 100 ng of both labeled DNA probes. After 2 nights of incubation at 37°C, the slides were washed and counterstained with antifade solution containing DAPI. Test and reference hybridization signals were scored in 50 nuclei for each tumor core under a 100x immersion objective. The ratio of the mean count for the test and the reference probe on the opposite chromosome arm of the same chromosome was reported as the relative copy number for the test gene. In preinvasive lesions, we took advantage of possible deletion of the FHIT locus on Chr. 3p to generate a copy number ratio as a sensitive measure of chromosomal imbalance between 3p and 3q. We previously reported the reliability of the assay by showing low inter-observer variability in FISH spot counting (E2).
Immunohistochemistry
Immunohistochemical staining was performed as previously described (E2).
Slides were deparaffinized and hydrated through a graded alcohol series before being placed in 3% H 2 0 2 -PBS blocking solution for 5 min to inhibit endogenous peroxidase activity. Slides were then digested with 0.01% trypsin at 37ºC for 15 min. Antigen unmasking was done in 10 mM citrate buffer, pH 6.0, for 10 min. Slides were incubated with pAkt primary antibody (Cell Signaling, Beverly, MA) diluted 1:500 in PBS overnight at 4ºC, and treated with the biotinylated secondary antibody for 30 min at room Data analysis included Spearman correlation coefficients, ANOVA and Kaplan-Meier survival estimates with Cox proportional hazards regression models. Survival analysis was calculated from date of diagnosis to date of death or last date of contact for those alive at the time of the analysis. Curves were compared by the log-rank test. All analyses were carried out with SAS statistical software (SAS Institute Inc., Cary, NC).
